WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced findings from a new multinational study demonstrating the efficacy of its Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs) in reducing central line-associated bloodstream infections (CLABSIs). Conducted across 12 intensive care units in eight hospitals located in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey, the prospective cohort study included over 6,670 ICU patients.
The results showed a significant 70.5% reduction in CLABSI rates among patients using Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ antimicrobial CVCs compared to those with non-impregnated catheters. The study also highlighted lower rates of infection with pathogens, including gram-negative bacteria such as Klebsiella pneumoniae and Escherichia coli, gram-positive bacteria including Staphylococcus aureus, and fungi such as Candida species.
Dr. Amy Bardin, VP of Clinical and Medical Affairs at Teleflex, explains that this multinational study suggests unprotected CVCs may pose a higher risk for CLABSI compared to chlorhexidine-impregnated CVCs, even with proper training and best practices like catheter care and barrier precautions.
The study maintained consistent training and procedural controls across groups, ensuring insertion techniques and barrier precautions were not confounding factors. Patients using the impregnated CVCs typically experienced longer ICU stays and higher device utilization ratios, indicating extended CVC use without a proportional increase in infection rates.
“Despite the inevitable variations in hospital environments and patient demographics globally, this study offers strong evidence of the clinical value of chlorhexidine-impregnated CVCs in minimizing infections, even in high-risk ICU settings,” added Dr. Bardin.
These findings support the performance of Teleflex’s antimicrobial technology in reducing incidences of CLABSI, a significant healthcare challenge with implications for patient outcomes and hospital costs. Studies like this further underscore the importance of adopting robust infection prevention measures in critical care environments.
By reinforcing the efficacy of Arrow Chlorhexidine-Impregnated CVCs, Teleflex continues to deliver evidence-based solutions that enhance infection prevention protocols and improve patient safety in healthcare settings worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.